Biomarker Discovery Outsourcing Services

Global Biomarker Discovery Outsourcing Services Market to Reach US$51.9 Billion by 2030

The global market for Biomarker Discovery Outsourcing Services estimated at US$16.5 Billion in the year 2024, is expected to reach US$51.9 Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Surrogate Endpoints, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$22.8 Billion by the end of the analysis period. Growth in the Predictive Biomarkers segment is estimated at 19.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 19.9% CAGR

The Biomarker Discovery Outsourcing Services market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 19.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Biomarker Discovery Outsourcing Services Market - Key Trends & Drivers Summarized

Why Is Biomarker Discovery Outsourcing Becoming a Critical Strategy for Drug Development?

Biomarker discovery has become a crucial element in modern drug development, enabling pharmaceutical and biotech companies to enhance drug efficacy, improve patient selection, and accelerate regulatory approvals. Given the growing complexity and cost of biomarker research, many companies are turning to outsourcing partners to streamline operations, reduce financial burdens, and leverage specialized expertise. Contract research organizations (CROs) and specialized biomarker discovery firms offer end-to-end services, including target identification, validation, bioinformatics analysis, and regulatory support, allowing pharmaceutical firms to focus on core research and commercialization strategies. The surge in demand for precision medicine and companion diagnostics has further fueled the need for biomarker discovery outsourcing. As drug developers increasingly rely on biomarkers to predict therapeutic responses, outsourcing partners are providing critical support in biomarker assay development and validation. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions has intensified the need for innovative biomarkers, prompting pharmaceutical companies to collaborate with external research organizations that have cutting-edge technologies and regulatory know-how.

How Are Technological Advancements Transforming Biomarker Discovery Outsourcing?

The rapid evolution of next-generation sequencing (NGS), proteomics, and metabolomics is reshaping the biomarker discovery landscape, enabling more precise and efficient identification of disease-specific molecular signatures. Artificial intelligence (AI) and machine learning are revolutionizing data analysis, allowing researchers to uncover previously undetectable biomarker correlations and improve patient stratification in clinical trials. These advanced technologies are helping outsourcing service providers enhance biomarker identification, validation, and predictive modeling, significantly reducing drug development timelines and costs. Furthermore, advances in bioinformatics and computational biology are enabling contract research organizations to provide more comprehensive biomarker discovery services. High-throughput screening, single-cell analysis, and multi-omics approaches are expanding the scope of biomarker research, ensuring a more accurate understanding of disease mechanisms. Additionally, the rise of liquid biopsy techniques, which allow for non-invasive biomarker detection, is gaining traction in outsourced biomarker discovery services, offering new avenues for real-time disease monitoring and early detection. As these technologies continue to evolve, outsourcing partners are becoming increasingly indispensable for pharmaceutical companies seeking to accelerate biomarker-driven drug development.

What Market Trends Are Driving the Growth of Biomarker Discovery Outsourcing?

One of the most significant trends driving biomarker discovery outsourcing is the growing emphasis on personalized medicine. As healthcare shifts toward tailored treatment strategies, pharmaceutical firms are leveraging outsourcing services to develop biomarkers that enable precise patient stratification and targeted therapies. This trend is particularly evident in oncology, where biomarker-driven drug development is playing a pivotal role in immunotherapy and targeted cancer treatments. Another major trend is the increasing collaboration between pharmaceutical companies and contract research organizations to accelerate drug discovery timelines. Outsourcing biomarker discovery allows drug developers to access cutting-edge technologies and specialized expertise without the need for extensive in-house investments. Additionally, regulatory agencies such as the FDA and EMA are placing greater emphasis on biomarker-driven drug approvals, incentivizing pharmaceutical firms to outsource biomarker validation and compliance support. The rise of decentralized and virtual clinical trials is also reshaping the biomarker discovery landscape, as remote biomarker collection and AI-powered data analysis gain traction.

What Are the Key Growth Drivers for the Biomarker Discovery Outsourcing Market?

The growth in the Biomarker Discovery Outsourcing Services market is driven by several factors including the increasing complexity of biomarker research, rising demand for precision medicine, and advancements in AI-driven data analytics. The high costs associated with in-house biomarker discovery are prompting pharmaceutical companies to seek external partners that can provide cost-effective and efficient biomarker solutions. The globalization of clinical trials and the need for multi-regional biomarker validation studies are also contributing to market expansion, as outsourcing enables drug developers to conduct studies across diverse patient populations. Additionally, the integration of big data analytics and cloud-based platforms is streamlining biomarker discovery workflows, improving data interpretation, and enhancing clinical trial success rates. As the demand for biomarker-driven therapeutics continues to grow, outsourcing is expected to play an increasingly pivotal role in accelerating drug development and advancing personalized medicine.

SCOPE OF STUDY:

The report analyzes the Biomarker Discovery Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers); Discovery Phase (Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase, Biomarker Selection Phase); Therapeutic Area (Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• AB Sciex LLC
• BioIVT LLC
• Charles River Laboratories, Inc.
• Creative Biolabs
• Crown Bioscience Inc.
• Discovery Life Sciences
• Eurofins Scientific SE
• Evotec SE
• Laboratory Corporation of America Holdings
• Metabolon, Inc.
• REPROCELL Inc.
• Sino Biological, Inc.
• Thermo Fisher Scientific, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.